Skip to search formSkip to main contentSkip to account menu

CAT-8015

Known as: Anti-CD22 Immunotoxin CAT-8015, GCR-8015, Immunotoxin CAT-8015 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

immunotoxin HA22

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Moxetumomab pasudotox. Inmunotoxina recombinante anti-CD22
Hairy cell leukemia (HCL) is a rare and incurable disease that represents approximately 2% of lymphoid leukemias. Treatment is… 
Review
2015
Review
2015
Immunoconjugates in the management of hairy cell leukemia.
2013
2013
Abstract 2425: Nucleosomal DNA assay development and utility as PoP biomarker.
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC Elevated baseline levels of circulating cell-free… 
2012
2012
Durability of complete remission by moxetumomab pasudotox (HA22 or CAT-8015) assessed by clone-specific real-time quantitative PCR (RQ-PCR).
2503^ Background: The anti-CD22 recombinant immunotoxin moxetumomab pasudotox, also known as HA22 or CAT-8015, was recently… 
2012
2012
Targeted immunotherapy for hairy cell leukemia.
In Journal of Clinical Oncology, Kreitman et al report the efficacy of anti-CD22 monoclonal antibody (mAb) conjugated to… 
Review
2011
Review
2011
Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia
Standard treatment for hairy cell leukemia (HCL) is markedly effective, but the constant decrease in disease-free survival… 
2010
2010
Phase I trial of recombinant immunotoxin CAT-8015 (HA22) in multiply relapsed hairy cell leukemia.
6523 Background: CAT-8015 (HA22) contains the Fv domains of the anti-CD22 Mab RFB4 and truncated pseudomonas exotoxin, inducing… 
2009
2009
Phase I Dose-Escalation Study of CAT-8015 (HA22), A CD22-Specific Targeted Immunotoxin, in Relapsed or Refractory Hairy Cell Leukemia.
2007
2007
Pre-Clinical Evaluation of the Anti-CD22 Immunotoxin CAT-8015 in Combination with Chemotherapy Agents for Childhood B-Precursor Acute Lymphoblastic Leukemia (Pre-B ALL).
Despite advances in curative treatment, childhood ALL remains a leading cause of cancer-related mortality in pediatrics and… 
2006
2006
Characterization of CAT-8015: A Pseudomonas exotoxin based immunotoxin for the treatment of CD22-related hematological malignancies
3728 Immunotoxins are a class of anti-cancer therapies that are hybrid proteins composed of a tumor-targeting monoclonal antibody… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)